CMPX - Compass Therapeutics, Inc.
About Compass Therapeutics, Inc. (https://www.compasstherapeutics.com)
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Thomas J. Schuetz | Chief Executive Officer & Vice Chairman | 1961 | $1,032,150 USD |
| Barry Shin | Chief Financial Officer | 1972 | $717,000 USD |
| Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary | 1983 | $648,000 USD |
| Bing Gong | Chief Scientific Officer | 1976 | $445,500 USD |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | – | – |
| Arjun Prasad | Chief Commercial Officer | 1978 | – |
| Cynthia A. Sirard | Chief Medical Officer | 1970 | – |
| James Kranz | Vice President and Head of Chemistry Manufacturing & Controls | – | – |
| Karin Herrera | Senior Vice President & Head of Clinical Operations | – | – |
| Neil L. Lerner | Senior Vice President & Chief Accounting Officer | 1967 | – |